Marc O Maybauer1,2, Dirk M Maybauer3,4, John F Fraser5, Lillian D Traber3, Martin Westphal3,6, Robert A Cox3, Ruksana Huda3, Yoshimitsu Y Nakano3, Perenlei Enkhbaatar3, Hal K Hawkins3, David N Herndon3, Daniel L Traber3. 1. Investigational Intensive Care Unit, University of Texas Medical Branch and Shriners Burns Hospital, 301 University Blvd., 77555-0833, Galveston, TX, USA. marc.maybauer@uni-ulm.de. 2. Department of Anesthesiology and Intensive Care, Sektion Anästhesiologische Pathophysiologie und Verfahrensentwicklung, University of Ulm, Steinhövelstrasse 9, 89075, Ulm, Germany. marc.maybauer@uni-ulm.de. 3. Departments of Anesthesiology, Pathology, and Surgery, Investigational Intensive Care Unit, University of Texas Medical Branch and Shriners Burns Hospital for Children at Galveston, Tex., USA. 4. Department of Anesthesiology and Intensive Care, Sektion Anästhesiologische Pathophysiologie und Verfahrensentwicklung, University of Ulm, Steinhövelstrasse 9, 89075, Ulm, Germany. 5. Royal Children's Hospital Burns Research Group and Prince Charles Hospital, University of Queensland, Brisbane, Australia. 6. Department of Anesthesiology and Intensive Care Medicine, University of Münster, Münster, Germany.
Abstract
OBJECTIVE: To investigate ceftazidime in acute lung injury (ALI) and sepsis. DESIGN AND SETTING: Prospective, randomized, controlled animal study in an investigational ICU at a university hospital. INTERVENTIONS: Eighteen female Merino sheep were prepared for chronic study and subjected to smoke inhalation and septic challenge according to an established protocol. MEASUREMENTS AND RESULTS: Whereas global hemodynamics and oxygenation remained stable in sham animals (no injury, no treatment), the injury contributed to a hypotensive-hyperdynamic circulation in the control group (smoke inhalation and sepsis, no treatment), as indicated by a significant increase in cardiac index) and heart rate and a drop in mean arterial pressure. Treatment with ceftazidime (smoke inhalation and sepsis, treatment group) stabilized cardiac index and heart rate and attenuated the decrease in mean arterial pressure. The deterioration in PaO2/FiO2 ratio and pulmonary shunt fraction (Qs/Qt) was significantly delayed and blunted by ceftazidime. At 24 h after injury a significant increase in airway obstruction scores of bronchi and bronchioles in both injured groups was observed. Ceftazidime significantly reduced airway obstruction vs. control animals. Whereas plasma nitrate/nitrite levels increased similarly in the two injured groups, lung 3-nitrotyrosine content remained at the baseline level in the ceftazidime group. CONCLUSIONS: In ovine lung injury ceftazidime improves global hemodynamics and oxygenation not only by bacterial clearance but also via reduction in toxic nitrogen species such as 3-nitrotyrosine. Therefore ceftazidime appears as a clinically relevant adjunct in the common setting of sepsis-associated lung injury.
OBJECTIVE: To investigate ceftazidime in acute lung injury (ALI) and sepsis. DESIGN AND SETTING: Prospective, randomized, controlled animal study in an investigational ICU at a university hospital. INTERVENTIONS: Eighteen female Merino sheep were prepared for chronic study and subjected to smoke inhalation and septic challenge according to an established protocol. MEASUREMENTS AND RESULTS: Whereas global hemodynamics and oxygenation remained stable in sham animals (no injury, no treatment), the injury contributed to a hypotensive-hyperdynamic circulation in the control group (smoke inhalation and sepsis, no treatment), as indicated by a significant increase in cardiac index) and heart rate and a drop in mean arterial pressure. Treatment with ceftazidime (smoke inhalation and sepsis, treatment group) stabilized cardiac index and heart rate and attenuated the decrease in mean arterial pressure. The deterioration in PaO2/FiO2 ratio and pulmonary shunt fraction (Qs/Qt) was significantly delayed and blunted by ceftazidime. At 24 h after injury a significant increase in airway obstruction scores of bronchi and bronchioles in both injured groups was observed. Ceftazidime significantly reduced airway obstruction vs. control animals. Whereas plasma nitrate/nitrite levels increased similarly in the two injured groups, lung 3-nitrotyrosine content remained at the baseline level in the ceftazidime group. CONCLUSIONS: In ovine lung injuryceftazidime improves global hemodynamics and oxygenation not only by bacterial clearance but also via reduction in toxic nitrogen species such as 3-nitrotyrosine. Therefore ceftazidime appears as a clinically relevant adjunct in the common setting of sepsis-associated lung injury.
Authors: Dirk M Maybauer; John R Salsbury; Martin Westphal; Marc O Maybauer; Andrew L Salzman; Csaba Szabó; Beena B Westphal-Varghese; Lillian D Traber; Daniel L Traber Journal: Shock Date: 2004-10 Impact factor: 3.454
Authors: Marc O Maybauer; Dirk M Maybauer; Lillian D Traber; Martin Westphal; Perenlei Enkhbaatar; Naoki Morita; Jeffrey M Jodoin; John P Heggers; David N Herndon; Daniel L Traber Journal: Shock Date: 2005-09 Impact factor: 3.454
Authors: Daniel P Healy; Paul A Silverman; Alice N Neely; Ian Alan Holder; George E Babcock Journal: Pharmacotherapy Date: 2002-05 Impact factor: 4.705
Authors: Dirk M Maybauer; Marc O Maybauer; Csaba Szabó; Martin Westphal; Lillian D Traber; Andrew L Salzman; David N Herndon; Daniel L Traber Journal: Burns Date: 2011-02-22 Impact factor: 2.744
Authors: Dirk M Maybauer; Marc O Maybauer; Csaba Szabó; Robert A Cox; Martin Westphal; Levente Kiss; Eszter M Horvath; Lillian D Traber; Hal K Hawkins; Andrew L Salzman; Garry J Southan; David N Herndon; Daniel L Traber Journal: Shock Date: 2011-02 Impact factor: 3.454
Authors: Yoshimitsu Nakano; Marc O Maybauer; Dirk M Maybauer; Perenlei Enkhbaatar; Daniel L Traber Journal: Burns Date: 2010-04-14 Impact factor: 2.744
Authors: Marc O Maybauer; Dirk M Maybauer; John F Fraser; Csaba Szabo; Martin Westphal; Levente Kiss; Eszter M Horvath; Yoshimitsu Nakano; David N Herndon; Lillian D Traber; Daniel L Traber Journal: Crit Care Date: 2010-11-26 Impact factor: 9.097
Authors: Saul Chemonges; Kiran Shekar; John-Paul Tung; Kimble R Dunster; Sara Diab; David Platts; Ryan P Watts; Shaun D Gregory; Samuel Foley; Gabriela Simonova; Charles McDonald; Rylan Hayes; Judith Bellpart; Daniel Timms; Michelle Chew; Yoke L Fung; Michael Toon; Marc O Maybauer; John F Fraser Journal: Biomed Res Int Date: 2014-03-25 Impact factor: 3.411
Authors: Collette C Jonkam; Kamna Bansal; Daniel L Traber; Atsumori Hamahata; Marc O Maybauer; Dirk M Maybauer; Robert A Cox; Matthias Lange; Rhykka L Connelly; Lillian D Traber; Clarisse D Djukom; John R Salsbury; David N Herndon; Perenlei Enkhbaatar Journal: Crit Care Date: 2009-02-17 Impact factor: 9.097
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Johan Groeneveld; Goran Hedenstierna; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Philipp Metnitz; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2008-01-04 Impact factor: 17.440